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doi:10.1016/j.jtcvs.2007.03.025n this issue, Momin and colleagues1 present timely translational evidence that
preoperative C-reactive protein (CRP) levels may predict the functionality and
patency of saphenous vein grafts (SVGs) after coronary artery bypass graft
CABG) procedures. Endothelial function was examined in saphenous vein seg-
ents from patients undergoing CABG who had been treated with simvastatin
reoperatively. CRP levels emerged as the only independent (negative) correlate of
ndothelial function, and they consequently open the window to the possibility that
atients with elevated CRP may be predisposed to postoperative SVG occlusions
mong other de novo atherosclerosis-related complications.
Although the immediate procedural success with SVGs is comparable with that
f arterial grafts, the greater susceptibility of SVGs to accelerated intimal hyper-
lasia and atherosclerosis remains a limiting factor. Improving endothelial function
s an important therapeutic approach in limiting aberrant saphenous vein
emodeling.
Notwithstanding the small cohort size of 76 subjects and some interpretational
imitations, Momin and colleagues1 are to be congratulated for evaluating how CRP
a critical player in inflammatory processes and a biomarker of atherosclerosis)
lters SVG vasoresponsiveness and how this, in turn, may influence the efficacy of
VGs. Insight on the interplay between serum CRP concentrations and SVG
ongevity are unfortunately lacking and would have greatly strengthened this work.
nasmuch as inflammation is increasingly recognized as the crux of atherosclerosis,
t would have been prudent for the authors to also monitor CRP values periopera-
ively and postoperatively. Concurrent expansion of the inflammatory marker panel
tudied to include serum amyloid A and fibrinogen (among others) that are closely
ssociated with the pathogenesis of atherosclerosis would also have been of great
nterest. Accordingly, a prospective study encompassing angiographic follow-ups
oupled with measurements of serum CRP and other endogenous inflammatory
gents in this and other similar cohorts may be warranted.
Prior CABG trials provide compelling evidence that graft patency is superior if
tatin regimens are initiated preoperatively. Fewer repeat revascularization proce-
ures were performed in these patients and occurrences of ischemic cardiovascular
vents were decreased. Currently, the ultimate target of statin treatments is to attain
ow-density lipoprotein (LDL) levels of less than 100 mg/dL. The study by Momin
nd coworkers1 refocuses this school of thought and reminds us that the benefits of
tatins are also deeply rooted in improved endothelial function, dampened inflam-
ation, and reduced thrombosis.2
Prospective epidemiologic studies have repeatedly proven that circulating high-
ensitivity CRP is an independent predictor of cardiovascular disease risk and
ortality. More interestingly, high-sensitivity CRP levels have been demonstratedo have greater prognostic value than that of LDL in predicting future cardiovascular
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Lvents.3 As such, the Centers for Disease Control and Pre-
ention and the American Heart Association have now
ade recommendations on the application of high-sensitiv-
ty CRP for the assessment of cardiovascular risk. The
esults reported by Momin and coworkers1 support this line
f thought and emphasize that perhaps aggressive manage-
ent of preoperative CRP levels may be one factor in
imiting SVG failure.
The endothelium acts as an interface for the blood and
he underlying vascular smooth vessel layer. Under normal
onditions, this dynamic organ releases a variety of sub-
tances that act in concert to promote vasodilation, anti-
hrombosis, and anti-inflammation.4 Endothelial dysfunc-
ion, which causes cacophony in this finely tuned biological
quilibrium, is a salient feature of atherosclerosis and occurs
n the absence of angiographic evidence of coronary artery
isease. On the flip side, one of the earliest indications of
ffective pharmacologic modulation of atherogenic risk is
n improvement in endothelial function, resonating the sig-
ificance of this endocrine organ in multiple cardiometa-
olic diseases.5
Endothelium-derived nitric oxide (NO) is constitutively
enerated from L-arginine by the enzymatic action of endo-
helial NO synthase (eNOS) and is a principal participant in
he maintenance of normal endothelial function. Two other
ritical, albeit contradictory, vasoregulatory products of the
ndothelium are prostacyclin and endothelin-1. Distur-
ances in the integrity of the endothelial monolayer accord-
ngly diminish NO and prostacyclin bioavailability and ac-
ivity. Concurrently, endothelin-1–evoked effects are
nhanced and escalated, thereby tipping the vascular ho-
eostatic balance in favor of events encouraged by newly
nveiled proatherogenic bioactive factors from the under-
ying smooth muscle layer. Any agent that further retards
he events upstream and downstream of NO and prostacy-
lin and/or promotes those of endothelin-1 could therefore
e detrimental in the diseased state.
CRP has been shown in in vitro models to inhibit endo-
helial cell eNOS transcription and translation, and limit
NOS activity and bioactivity, with ultimate reductions in
asal and stimulated NO release.6,7 Prostacyclin secretion
rom endothelial cells was also appreciably reduced by CRP in
itro.8 In contrast, CRP substantially increased endothelin-1
nd interleukin-6 release from human saphenous vein en-
othelial cells (HSVEC) in vitro.9 Additionally, CRP up-
egulated HSVEC protein and messenger RNA levels of the
eceptor for advanced glycation end products, which is
ostulated to participate in diabetes-linked endothelial dys-
unction and atherosclerosis.10 Aberrations in the endothe-
ium and its function can be provoked by oxidized LDL
cting via the lectin–like oxidized LDL receptor-1 (LOX-1)
rotein. These abnormalities can be exacerbated by CRP,
hich has been found to elevate LOX-1 mRNA and protein p
78 The Journal of Thoracic and Cardiovascular Surgery ● Auguevels.11 CRP has further been reported to facilitate endo-
helial cell apoptosis6 and attenuate key components in-
olved in endothelial progenitor cell angiogenesis.12 Plas-
inogen activator inhibitor-1 and tissue plasminogen
ctivator are fundamental to fibrinolysis and thrombosis.
hereas CRP increased mRNA, protein, and activity re-
ease of plasminogen activator inhibitor-1 from endothelial
ells in vitro, the converse was true for tissue plasminogen
ctivator.13,14 CRP is thus prothrombotic and an antifibrino-
ytic. Taken together, the cumulative laboratory evidence
uggests that human recombinant CRP, at concentrations
nown to predict vascular disease, triggers a rainbow of
vents in endothelial cells that bias the pro-inflammatory
nd pro-atherosclerotic phenotype.
In addition to modifying the endothelium, CRP has dem-
nstrated well-documented influences on monocytes and
mooth muscle cells.15 CRP induces the expression of mac-
ophage chemoattractant protein-1 (MCP-1), intercellular
dhesion molecule-1 (ICAM-1), and vascular cell adhesion
olecule-1 (VCAM-1) in vitro.16,17 CRP deposition in the
rterial wall appears to precede monocyte infiltration, and
RP is chemotactic for human monocytes.18 Although there
s strong evidence suggesting that CRP exerts a proathero-
enic influence via monocytes and macrophages, there also
ppears to be a more direct interaction of CRP with vascular
issues. Vascular smooth muscle cells are a target of
roatherogenic modification by CRP, most notably via in-
reased angiotensin type 1 receptor (AT1-R) protein, AT1-R
RNA, and AT1-R binding sites, while promoting smooth
uscle cell migration and proliferation.19
Although there is some evidence that CRP is capable of
irectly and indirectly modulating endothelial function, the
ata have been somewhat confounding. Initial in vivo re-
orts of a negative correlation between endothelial function
nd circulating levels of CRP in patients20,21 were brought
nto question by the demonstration that physiologically rel-
vant concentrations of CRP directly caused vasodilation of
solated human internal thoracic arteries.22 More recently,
amirani and colleagues18 demonstrated that 1-hour adminis-
ration of exogenous CRP in perfused porcine coronary arte-
ioles inhibited vasorelaxation elicited by 5-hydroxytryptamine
n vitro.23 Aside from these reports, little is known about the
anner in which long-term exposure to CRP may affect
asoreactivity and endothelial function. However, the latest
reliminary studies from our group have suggested that
ndothelial function may be impaired in CRP overexpress-
ng mice. The report by Momin and colleagues1 will belat-
dly spark interest and catalyze studies delving into this
orely neglected area of research.
The results presented in the study by Momin and asso-
iates1 reinforce the concept that in patients slated for
ABG procedures, statins are essential preoperative cardio-
rotective agents. Statins lower CRP levels profoundly, and
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Lhis effect may be independently linked to their cardiopro-
ectiveness.24,25 It is unknown what dosage of simvastatin
hese patients were prescribed. However, it does raise the
onsideration that in patients classified with high-risk CRP
evels, more aggressive statin treatment (eg, 80 mg atorva-
tatin or 20–40 mg rosuvastatin), which would also sup-
ress circulating CRP levels, may be necessary and should
e initiated before CABG surgery.26 Side-effects (eg, rhab-
omyolysis, hepatic dysfunction, myopathy) with such
harmacologic doses of statins are possible but minimal.
he hunt to determine whether the eventual pharmaco-
ogical panacea for SVG longevity lies with such inten-
ive statin regimens or combinations of optimal LDL-
ontrolling statin dosages with anti-inflammatory agents
s reliant on more large-scale longitudinal studies. The in
itro evidence demonstrating CRP as a vasorelaxant in
horacic arteries22 also prompts the need to perform par-
llel translational studies aimed at determining whether
orrelation observed between CRP and SVG endothelial
unction in the Momin and coworkers1 is mirrored in
rterial grafts intended for CABGs. SVG patency is af-
ected by multiple patient-specific and procedure-specific
eatures, and elevated CRP levels is only one such factor.
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